ABSTRACT
The novel coronavirus severe acute respiratory syndrome Corona Virus-2 (SARS-CoV--2) has become a pandemic, as declared by WHO in March 2020 producing deleterious effects on patients worldwide. The angiotensin-converting enzyme-2 (ACE-2) has been recognized as the co-receptor for SARS-CoV-2 infections and may act as a therapeutic step in blocking the enzyme to re-duce SARS-CoV-2 expression and further cellular entry. Presently, the role of ACE-2 in coron-avirus disease 2019 (COVID-19) infection has been known and the experts have started working on the enzyme ACE-2 for the management and treatment of this pandemic disease. The binding of spike (S) protein of SARS-CoV-2 to these receptors is the most important step and plays a key role in viral replication, thus this enzyme is becoming the doorway for the entry and spread in the human body causing asymptomatic pneumonia and severe of which is leading to death. As no specific method to prevent and treat this disease is available, the use of ACE-2 as a targeting ligand with COVID-19 virus spike protein could be helpful in the proper management of SARS-CoV-2 pneu-monia.Copyright © 2021 Bentham Science Publishers.
ABSTRACT
Objectives: To determine the correlation between lymphocyte count and A-DROP score in COVID-19 patients and their role in predicting poor outcomes. Methods: This retrospective observational single-center study was conducted in a tertiary care hospital in Vidisha district, India. COVID-19 patients were included in this study, who were admitted to ICU and the COVID Care Centre from August 2020 to October 2020. Demographic profile, clinical characteristics, medical history, A-DROP score, complete blood counts including lymphocyte counts (on admission), the severity of the disease course, and duration of hospitalization were collected. The correlation between lymphopenia and A-DROP score was determined, and their role in predicting poor outcomes was investigated. Results: This study included 220 patients, among which 134 were male, and 86 were female [mean age (48.98±16.98) years, 95% CI: 46.72-51.23]. Lymphocyte count in COVID-19 patients negatively correlated with the A-DROP score (r=-0.67, P<0.001). The area under the ROC curve was 0.892 (95% CI: 0.80-0.98, P<0.001) for the lymphocyte count, and the area under the ROC curve was 0.93 (95% CI: 0.84-1.00, P<0.001) for lymphocyte count-A-DROP. Conclusion: Lymphocyte count along with the A-DROP score on admission could be used to predict the severity of COVID-19 pneumonia and unfavorable outcome.
ABSTRACT
Noval corona virus 2019 which also called as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lead to severe pneumonia and acute respiratory distress syndrome. CPAP and HFNC as been used as non invasive mode of ventilation during this pandemicity declared by the WHO as a global public health emergency [1].HFNC is a recent therapy for covid-19 pneumonia, curiosity to know more about HFNC and CPAP lead us to conducted a retrospective study of CPAP vs HFNC in our institute for covid-19 positive patients treatment admitted in ICU during 19 October 2020 to 30 January 2021. A sample size of 26 patients included in our study with mean spo2 at the time of admission of CPAP group 85% and HFNC group 89% and mean age is comparable in both groups. We found more patient discharge and less death (60%) in HFNC group as compare to CPAP group were death is (91%) in our ICU setting. As well as comorbities are more associated with HFNC group (80%) as compare to CPAP group (36.4%). The limitation is that it is single centre study, so further large-sample studies will be required to validate the conclusion and preferably through prospective randomized trials. © 2021 Universitatea de Vest Vasile Goldis din Arad. All rights resrved.